State-dependent verapamil block of the cloned human Cav3.1 T-type Ca2+ channel

Molecular Pharmacology

Volumn 70, Issue 2, 2006, Pages 718-726

  Freeze, Benjamin S ^a   McNulty, Megan M ^a   Hanck, Dorothy A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC 6094 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; VERAPAMIL;

ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DEPOLARIZATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; HUMANS; ION CHANNEL GATING; PROTEIN CONFORMATION; VERAPAMIL;

EID: 33746238092     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.023473     Document Type: Article

References (42)

1. 2+ current of mouse spermatogenic cells. Mol Pharmacol 53:1104-1111.
2. 2+ antagonist RO 40-5967 on endothelium-dependent responses of isolated arteries. J Cardiovasc Pharmacol 23:869-876.
3. Budavari S (1996) The Merck Index: an Encyclopedia of Chemicals, Drugs, and Biologicals. Merck, Whitehouse Station, NJ.
4. Catacuzzeno L, Trequattrini C, Petris A, and Franciolini F (1999) Mechanism of verapamil block of a neuronal delayed rectifier K channel: active form of the blocker and location of its binding domain. Br J Pharmacol 126:1699-1706.
5. 2+ channels. Science (Wash DC) 302:1416-1418.
6. Clozel JP, Ertel EA, and Ertel SI (1997) Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl 15:S17-S25.
7. + channel block by verapamil and related compounds in rat alveolar epithelial cells. J Gen Physiol 106:745-779.
8. 2+ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol 66:1236-1247.
9. v3.1 variants from the human T-type calcium channel gene CACNA1G: alternative structures, developmental expression, and biophysical variations. Proteins 64:320-342.
10. Fareh S, Benardeau A, and Nattel S (2001) Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res 49:762-770.
11. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 100:2191-2197.
12. Fox AP, Nowycky MC, and Tsien RW (1987a) Kinetic and pharmacological properties distinguishing three types of calcium currents in chick sensory neurones. J Physiol 394:149-172.
13. Fox AP, Nowycky MC, and Tsien RW (1987b) Single-channel recordings of three types of calcium channels in chick sensory neurones. J Physiol 394:173-200.
14. Hadley RW and Lederer WJ (1995) Nifedipine inhibits movement of cardiac calcium channels through late, but not early, gating transitions. Am J Physiol 269:H1784-H1790.
15. 2+ channels. Jpn J Pharmacol 85:339-350.
16. v3.1 isotype of T-type calcium channels. J Physiol 555:331-344.
17. Hockerman GH, Johnson BD, Abbott MR, Scheuer T, and Catterall WA (1997) Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the α1 subunit. J Biol Chem 272:18759-18765.
18. Hockerman GH, Johnson BD, Scheuer T, and Catterall WA (1995) Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels. J Biol Chem 270:22119-22122.
19. Jensen LJ, Salomonsson M, Jensen BL, and Holstein-Rathlou NH (2004) Depolarization-induced calcium influx in rat mesenteric small arterioles is mediated exclusively via mibefradil-sensitive calcium channels. Br J Pharmacol 142:709-718.
20. Johnson BD, Hockerman GH, Scheuer T, and Catterall WA (1996) Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines. Mol Pharmacol 50:1388-1400.
21. Karila-Cohen D, Dubois-Rande JL, Giudicelli JF, and Berdeaux A (1996) Effects of mibefradil on large and small coronary arteries in conscious dogs: role of vascular endothelium. J Cardiovasc Pharmacol 28:271-277.
22. Kato M, Dote K, Sasaki S, Takemoto H, Habara S, and Hasegawa D (2004) Intracoronary verapamil rapidly terminates reperfusion tachyarrhythmias in acute myocardial infarction. Chest 126:702-708.
23. 2+ channels in rat aorta smooth muscle cells in primary culture. Circ Res 67:469-480.
24. v3.1 calcium channel by alpha 2 delta 2 and gamma 5 subunits. Arch Biochem Biophys 425:207-213.
25. Lacinova L, Klugbauer N, and Hofmann F (2002) Gating of the expressed Cav3.1 calcium channel. FEBS Lett 531:235-240.
26. Lam E, Skarsgard P, and Laher I (1998) Inhibition of myogenic tone by mibefradil in rat cerebral arteries. Eur J Pharmacol 358:165-168.
27. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, and Hanck DA (2000) Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 295:302-308.
28. ++ channels. J Pharmacol Exp Ther 271:1483-1488.
29. 2+ channels by Ro 40-5967. Circ Res 75:144-148.
30. Moosmang S, Haider N, Bruderl B, Welling A, and Hofmann F (2006) Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2. Circ Res 98:105-110.
31. Moosmang S, Schulla V, Welling A, Feil R, Feil S, Wegener JW, Hofmann F, and Klugbauer N (2003) Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO (Eur Mol Biol Organ) J 22:6027-6034.
32. Motoike HK, Bodi I, Nakayama H, Schwartz A, and Varadi G (1999) A region in IVS5 of the human cardiac L-type calcium channel is required for the use-dependent block by phenylalkylamines and benzothiazepines. J Biol Chem 274:9409-9420.
33. Nawrath H and Wegener JW (1997) Kinetics and state-dependent effects of verapamil on cardiac L-type calcium channels. Naunyn-Schmiedeberg's Arch Pharmacol 355:79-86.
34. Ohashi N, Mitamura H, Tanimoto K, Fukuda Y, Kinebuchi O, Kurita Y, Shiroshita-Takeshita A, Miyoshi S, Hara M, Takatsuki S, et al. (2004) A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling. J Cardiovasc Pharmacol 44:386-392.
35. Perez-Reyes E (2003) Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 83:117-161.
36. Perez-Reyes E, Cribbs LL, Daud A, Lacerda AE, Barclay J, Williamson MP, Fox M, Rees M, and Lee JH (1998) Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature (Lond) 391:896-900.
37. Pritchett EL (2004) Symptomatic arrhythmia recurrence as an outcome in clinical trials of antiarrhythmic drug therapy. Heart Rhythm 1:B36-B40.
38. + channel mKv1.3 by the phenylalkylamine verapamil: kinetic aspects of block and disruption of accumulation of block by a single point mutation. Br J Pharmacol 131:1275-1284.
39. 2+ selectivity of alpha1G T-type calcium channels. Biophys J 79:3052-3062.
40. Sheets MF and Hanck DA (2003) Molecular action of lidocaine on the voltage sensors of sodium channels. J Gen Physiol 121:163-175.
41. VanBavel E, Sorop O, Andreasen D, Pfaffendorf M, and Jensen BL (2002) Role of T-type calcium channels in myogenic tone of skeletal muscle resistance arteries. Am J Physiol 283:H2239-H2243.
42. Welker HA, Wiltshire H, and Bullingham R (1998) Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 35:405-423.